Public Health Emergency: SOLIDARITY TRIAL Philippines

University of the Philippines1,314 enrolled

Overview

This study is an adaptive, randomized, open-label, controlled clinical trial utilizing an adaptive design to compare effects of repurposed drugs with local standard of care alone on major inpatient hospital outcomes. This is performed worldwide in collaboration with WHO.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

1,314

Conditions

Covid19

Interventions

RemdesivirDRUG

Two intravenous loading doses, then daily infusion for 10 days

HydroxychloroquineDRUG

Two oral loading doses, then orally twice daily for 10 days

Lopinavir / RitonavirDRUG

Orally twice daily for 14 days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Consenting adults (age ≥18) hospitalised with the following criteria will be included in the study: 1. Probable or confirmed COVID-19 regardless of severity, i.e., mild, moderate and severe cases 2. Not already receiving any of the study drugs 3. Without known allergy or contraindications to any of the study drugs (in the view of the physician responsible for their care), and 4. Without anticipated transfer within 72 hours to a non-study hospital. Exclusion Criteria: * Patients with contraindications to any of the study drugs.

Locations (25)

Outcomes

Primary Outcomes

All-cause mortality

Time frame: Number of days from hospital admission up to 28 days post discharge

Secondary Outcomes

Duration of hospital stay

Time frame: Number of days from hospital admission to discharge up to 28 days post admission

Time to first receiving ventilation

Time frame: Number of days from hospital admission to day of receiving ventilatory support up to 28 days post admission

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.